Choice of P2Y12 Inhibitors After Acute Coronary Syndrome

Akyuz et al 1 Akyuz S, Calik AN, Yaylak B, Onuk T, Eren S, Kolak Z, Mollaalioglu F, Durak F, Cetin M, Tanboga IH. Comparison of ticagrelor and clopidogrel in patients with acute coronary syndrome at high bleeding or ischemic risk. [published online October 22, 2023] Am J Cardiol doi:10.1016/j.amjcard.2023.10.046. Google Scholar explored the effectiveness of ticagrelor compared with clopidogrel in patients with acute coronary syndrome (ACS) in a registry-based cohort study of 5,713 patients. The main finding was that ticagrelor, after logistic regression model adjustment and propensity matching, was not associated with a significantly lower mortality risk than clopidogrel, irrespective of patient bleeding and ischemic risk.